Clinical Trials Logo

Stage II Prostate Cancer AJCC v8 clinical trials

View clinical trials related to Stage II Prostate Cancer AJCC v8.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04927559 Terminated - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

Start date: December 18, 2020
Phase:
Study type: Observational

This study assesses the health literacy and understanding of radiation therapy information during consultation in patients with prostate or breast cancer undergoing definitive radiation therapy. Health literacy is defined as "the capacity to obtain, process, and understand health information and services to enable sound health decisions." Information gained from this study, may help researchers develop appropriate modalities to enhance comprehension of radiation therapy, and therefore allow for improved patient decision making with medical treatment.

NCT ID: NCT04457245 Terminated - Clinical trials for Stage III Prostate Cancer AJCC v8

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

PSMA-dRT
Start date: August 14, 2020
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared to dRT without PSMA PET (standard dRT).

NCT ID: NCT03570476 Terminated - Clinical trials for Stage II Prostate Cancer AJCC v8

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Start date: September 11, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.